Literature DB >> 6711432

Step-down treatment of mild systemic hypertension.

F A Finnerty.   

Abstract

Previous studies have shown that controlling the diastolic blood pressure (BP) for 6 months frequently permits the use of fewer drugs in lower doses in most patients with moderately severe and severe systemic hypertension. Prompted by these observations, the dosage of chlorthalidone (monotherapy) was decreased in a stepwise fashion and then discontinued after the diastolic BP had been maintained below 85 mm Hg for 6 months in 67 patients with mild systemic hypertension (diastolic BP 92 to 104 mm Hg). These patients have been followed for 48 months. Initially, a dose of 25 mg/day of chlorthalidone was just as effective as 50 mg in controlling the diastolic BP in all patients, and it was not until the dose was reduced to 12.5 mg/day that the diastolic BP increased in 8 patients. Annoying symptoms and metabolic side effects were decreased or eliminated. Chlorthalidone therapy was discontinued in 36 of the 67 patients. The ability to discontinue therapy in these patients suggests the possibility of intermittent, rather than continuous, lifelong therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711432     DOI: 10.1016/0002-9149(84)90084-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Risks versus benefits of withdrawing antihypertensive therapy.

Authors:  H P Schobel; R E Schmieder; F H Messerli
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

2.  Clinical predictors of treatment reduction in hypertensive patients.

Authors:  J F Steiner; S D Fihn; T D Koepsell; B Blair; K Kelleher; D D'Alessandro; T S Inui
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

3.  Does Antihypertensive Therapy Need to be Life-Long?

Authors:  J Lemelin
Journal:  Can Fam Physician       Date:  1989-09       Impact factor: 3.275

Review 4.  When is discontinuation of antihypertensive therapy indicated?

Authors:  R E Schmieder; J K Rockstroh
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

5.  The likelihood of remaining normotensive following antihypertensive drug withdrawal.

Authors:  A Mitchell; R B Haynes; C A Adsett; A Bellissimo; N Wilczynski
Journal:  J Gen Intern Med       Date:  1989 May-Jun       Impact factor: 5.128

Review 6.  Withdrawal of antihypertensive therapy in the elderly. The issues.

Authors:  M D Fotherby
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

Review 7.  Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.

Authors:  B Dahlöf
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.